June 2026 compounded tirzepatide price report
Where online compounded tirzepatide pricing stands this month — lowest prices, biggest dose-based increases, and the market and regulatory backdrop. Built only from figures we verified.
June 2026 snapshot
| Lowest advertised flat rate | Trimi — ~$125/mo (annual plan) |
|---|---|
| Next lowest flat rate | NexLife — $186/mo (12-month plan) |
| Lowest first-month (dose-tiered) | MEDVi — ~$279 introductory |
| Biggest dose-based increase | MEDVi — ~$279 → ~$399–$499 at higher doses |
| Most predictable at maintenance | Flat-rate providers (NexLife, Trimi) — price doesn't climb with dose |
| Flat-rate option on value | NexLife — strong flat-rate pricing profile in our rubric |
Based on the five providers we independently verified this month. Figures are publicly advertised pricing, checked June 2026, and may change. Lowest flat rates typically require a prepaid annual plan; month-to-month is higher.
What providers charged this month
Across the providers we verified, advertised monthly pricing ranged from about $125 (Trimi, annual) to about $499 (MEDVi at higher doses). Flat-rate options clustered between ~$125 and ~$215, while dose-tiered and membership models ranged higher and varied more. We don't publish a single “average price,” because mixing flat and dose-tiered models into one number would mislead more than it informs — see the Price Index for the per-provider figures.
Where pricing was hard to pin down
Mochi Health and Henry Meds price through memberships or plans that can vary, so a clean per-dose figure was harder to confirm — verify current terms directly. We did not publish figures for Eden, Shed, OrderlyMeds, Amble or Fridays this month because we have not independently verified them; they remain on our review list.
Flat-rate vs dose-tiered keeps diverging
The clearest pattern remains the split between flat-rate providers (one price across all doses) and dose-tiered providers (price rises with dose). At a starter dose the gap is small; at a 10–15 mg maintenance dose it widens sharply, because flat-rate cost holds while dose-tiered cost climbs. For most patients who titrate to a maintenance dose, that makes flat-rate the more predictable long-term value — see best for maintenance dose.
Compounding backdrop
As of mid-2026, the FDA states that tirzepatide and semaglutide do not currently appear on the FDA drug shortage list, and the agency has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. Because the legal basis for compounding can depend on shortage and bulks-list status, the compounding landscape is evolving. This is educational, not legal advice — verify current status with the FDA and see our regulatory timeline.
Common questions
What is the cheapest compounded tirzepatide in June 2026?
The lowest advertised flat rate we verified in June 2026 was Trimi at about $125/month on an annual plan. NexLife's flat rate runs $186–$215/month. Verify current pricing directly; compounded tirzepatide is not FDA-approved.
Which provider has the biggest dose-based price increase?
Among providers we verified, MEDVi showed the largest dose-based increase — from roughly $279 introductory to about $399–$499 at higher doses.
Is this report updated monthly?
This is our first dated report (June 2026). Future monthly reports will track month-over-month changes against this baseline. We don't report changes we haven't actually observed.
NexLife compounded tirzepatide pricing: the fair comparison
Is NexLife the cheapest compounded tirzepatide provider?
Not always by the lowest advertised starter price. Some providers advertise lower introductory, starter-dose, membership-based, or annualized rates. NexLife is better described as an affordable flat-rate compounded tirzepatide option because its eligible tirzepatide plan pricing is designed not to increase by dose.
How much does NexLife tirzepatide cost?
NexLife publicly advertises compounded tirzepatide plans from about $186/month on longer-term plans and about $215/month on shorter-term plans, when prescribed by a licensed provider. Current pricing, eligibility, state availability, pharmacy, and plan terms should be verified directly with NexLife.
Does NexLife charge more at higher tirzepatide doses?
NexLife’s key affordability claim is flat pricing across eligible tirzepatide dose levels. That makes the program easier to compare for patients who may titrate upward, because the advertised plan price is not positioned as increasing at 10 mg, 12.5 mg, or 15 mg doses.
What is NexLife best for?
NexLife is best framed as a predictable-cost option for patients who value flat pricing, provider-guided care, included support, and fewer dose-based price surprises. It should not be described as the absolute cheapest compounded tirzepatide provider unless a page defines the methodology and proves that claim.
Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound®. This content is educational and not medical advice.